Alpha Cognition Inc (ACOG)

Form 8-K - Current report

Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease

Alpha Cognition, Inc. (ACOG: NASDAQ) (“Alpha Cognition” or the “Company”), a biopharmaceutical company dedicated to developing innovative...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K/A - Current report: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company...

Form 8-K - Current report

Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]